ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC
ORIC Pharmaceuticals (NASDAQ: ORIC) has announced an upcoming presentation of initial data from their Phase 1b trial of ORIC-944. The trial evaluates the combination of ORIC-944 with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC).
The presentation will take place during a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. Investors can access the presentation through phone participation with pre-registration or via webcast through the company's website. The webcast recording will be available for 90 days after the presentation.
ORIC Pharmaceuticals (NASDAQ: ORIC) ha annunciato una prossima presentazione dei dati iniziali del loro studio di Fase 1b su ORIC-944. Lo studio valuta la combinazione di ORIC-944 con inibitori del recettore degli androgeni in pazienti con carcinoma prostatico metastatico resistente alla castrazione (mCRPC).
La presentazione si terrà durante una conference call e un webcast il mercoledì 28 maggio 2025, alle 16:30 ET. Gli investitori potranno partecipare telefonicamente previa registrazione o seguire il webcast tramite il sito web dell'azienda. La registrazione del webcast sarà disponibile per 90 giorni dopo la presentazione.
ORIC Pharmaceuticals (NASDAQ: ORIC) ha anunciado una próxima presentación de datos iniciales de su ensayo de Fase 1b de ORIC-944. El ensayo evalúa la combinación de ORIC-944 con inhibidores del receptor de andrógenos en pacientes con cáncer de próstata metastásico resistente a la castración (mCRPC).
La presentación se realizará durante una llamada en conferencia y webcast el miércoles 28 de mayo de 2025 a las 4:30 p.m. ET. Los inversores podrán acceder a la presentación mediante participación telefónica con preregistro o a través del webcast en el sitio web de la compañía. La grabación del webcast estará disponible durante 90 días después de la presentación.
ORIC Pharmaceuticals (NASDAQ: ORIC)는 ORIC-944의 1b상 초기 데이터 발표를 예고했습니다. 이 임상시험은 전이성 거세 저항성 전립선암(mCRPC) 환자를 대상으로 ORIC-944와 안드로겐 수용체 억제제 병용요법을 평가합니다.
발표는 2025년 5월 28일 수요일 오후 4시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트로 진행됩니다. 투자자들은 사전 등록을 통해 전화 참여하거나 회사 웹사이트를 통해 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 발표 후 90일간 제공됩니다.
ORIC Pharmaceuticals (NASDAQ : ORIC) a annoncé une prochaine présentation des données initiales de son essai de phase 1b sur ORIC-944. L'étude évalue la combinaison d'ORIC-944 avec des inhibiteurs du récepteur des androgènes chez des patients atteints d'un cancer de la prostate métastatique résistant à la castration (mCRPC).
La présentation aura lieu lors d'une conférence téléphonique et d'un webcast le mercredi 28 mai 2025 à 16h30 ET. Les investisseurs pourront accéder à la présentation par téléphone avec inscription préalable ou via le webcast sur le site internet de la société. L'enregistrement du webcast sera disponible pendant 90 jours après la présentation.
ORIC Pharmaceuticals (NASDAQ: ORIC) hat eine bevorstehende Präsentation erster Daten aus ihrer Phase-1b-Studie zu ORIC-944 angekündigt. Die Studie bewertet die Kombination von ORIC-944 mit Androgenrezeptor-Inhibitoren bei Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC).
Die Präsentation findet im Rahmen eines Telefonkonferenz und Webcasts am Mittwoch, den 28. Mai 2025, um 16:30 Uhr ET statt. Investoren können über eine telefonische Teilnahme mit Voranmeldung oder per Webcast über die Webseite des Unternehmens teilnehmen. Die Aufzeichnung des Webcasts wird für 90 Tage nach der Präsentation verfügbar sein.
- None.
- None.
Conference Call and Webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET.
To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
About ORIC-944
ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit. ORIC-944 was initially evaluated as a single agent in a Phase 1b trial in patients with advanced prostate cancer and demonstrated potential best-in-class drug properties, including clinical half-life of approximately 20 hours, robust target engagement and a favorable safety profile. ORIC-944 is currently being evaluated in combination with ERLEADA® (apalutamide) and in combination with NUBEQA® (darolutamide) in an ongoing Phase 1b trial for metastatic castration resistant prostate cancer.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the continued clinical development of ORIC-944; statements regarding the potential best-in-class properties of ORIC-944; the potential advantages of ORIC-944 and ORIC’s other programs; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section titled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 5, 2025, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
What is ORIC Pharmaceuticals presenting in their May 28, 2025 conference call?
How can investors access ORIC Pharmaceuticals' May 28 presentation?
How long will ORIC's May 28 presentation webcast be available for replay?
What type of cancer treatment is ORIC-944 being tested for?
